
    
      This was a single blind randomized controlled trial. Forty patients of FM group were assigned
      randomly to 2 study groups: 20 patients will be part of the experimental group (EG) that will
      perform a neuromuscular treatment using the vertical whole body vibration platform and
      another 20 will constitute the control group (CG). All these subjects will sign the
      corresponding informed consent for their participation in the study, according to the ethical
      criteria established in the Helsinki Declaration. The study took place between January and
      Juny 2019. Two groups of variables were analyzed in the present study three times: before,
      after and follow-up after three months of the intervention.
    
  